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Midkine is expressed by infiltrating macrophages in
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Background: Neointimal hyperplasia is strikingly suppressed in an endothelium injury model in mice deficient in the
growth factor midkine. Knockdown of midkine expression by means of antisense oligonucleotide or small interfering
RNA has been shown to lead to suppression of neointimal hyperplasia in a balloon injury model and a rabbit vein graft
model; therefore, midkine is an essential factor for neointimal hyperplasia. These findings, however, do not necessarily
apply to the function of midkine in vascular stenoses such as in-stent restenosis, because human vascular stenosis is often
accompanied by atherosclerosis.
Methods: We investigated midkine expression in the neointima induced by implantation of a bare metal stent in the
atheromatous lesions of hypercholesterolemic rabbits. We analyzed midkine expression during a THP-1 cell differenti-
ation and in peritoneal macrophages exposed to low-density lipoprotein or oxidized low-density lipoprotein.
Results: Midkine expression reached the maximum level within 7 days after stenting and was detected in infiltrating
macrophages. Differentiation of THP-1 cells to macrophage-like cells did not trigger midkine expression. Neither
low-density lipoprotein nor oxidized low-density lipoprotein enhanced midkine expression in peritoneal macrophages
that had been activated by thioglycollate, although these cells expressed a significant amount of midkine.
Conclusion: The results indicate that macrophages are the major source of midkine in the atherosclerotic neointima. The
amount of midkine expressed in macrophages may be sufficient (ie, further enhancement of the expression is not
necessary) for the pathogenesis, because oxidized low-density lipoprotein stimulation did not induce the midkine
expression. ( J Vasc Surg 2008;47:1322-9.)
Clinical Relevance: The growth factor midkine is induced during vascular stenosis in mouse and rat models with normal
diet. Knockdown of midkine expression suppresses neointimal hyperplasia. The vascular response after stenting differs
from that after balloon injury in that the inflammation is more prolonged and the accumulation of macrophages is more
abundant in stent-injured vessel. We found here that macrophages are the major source of midkine in the atherosclerotic
neointima of in-stent restenosis in hypercholesterolemic rabbits. Our data suggest that midkine has an important role in
in-stent restenosis of atherosclerotic vessels and is a candidate molecular target to prevent in-stent restenosis.The in-stent stenosis rate is 15% to 20% for ideal
coronary lesions but may increase to 30% to 60% for pa-
tients with complex lesions such as small vessels, diffuse
atheromatous, and bifurcation lesions.1 Stenting for pe-
ripheral vessels has the same problem.2 Thus, although
drug-eluting stents dramatically reduce the incidence of
restenosis, restenosis still remains a crucial problem, as in
the case of late thrombosis resulting from insufficient reen-
dothelialization.3 Restenosis after balloon angioplasty is
considered to arise through a combination of inadequate or
deleterious arterial remodeling and neointimal hyperplasia,
whereas in-stent restenosis arises primarily from neointimal
hyperplasia.4
Angioplasty and stenting both cause injury to the vas-
cular wall and initiate platelet accumulation and activation
as well as smooth muscle cell activation. These effects in
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1322turn cause smooth muscle cells to migrate from the media
to the intima, where they proliferate, leading to neointima
hyperplasia.5 However, the vascular response after stenting
differs from that after balloon injury in that the inflamma-
tory response in stent-injured vessels is more prolonged and
the accumulation of macrophages is more abundant than in
balloon-injured vessels.6-8
Because restenosis in patients often accompanies ath-
erosclerosis, hypercholesterolemic animal models are used
to study the pathogenic mechanisms underlying resteno-
sis.9 A high-cholesterol diet increases blood low-density
lipoprotein (LDL), which carries cholesterol to peripheral
tissues. Excess LDL is oxidized (oxLDL), and oxLDL is
then recognized by a scavenger receptor on infiltrating
macrophages in the vessel wall and consequently generates
foam cells.10,11
Midkine is a heparin-binding growth factor and has
50% sequence identity with pleiotrophin/heparin-binding
growth-associated molecule (PTN/HB-GAM).12-15 These
two form a family distinct from other heparin-binding
growth factors. Midkine is involved in inflammation, as
revealed by studies involving midkine-deficient (Mdk/)
mice. Ischemic reperfusion-induced renal damage,16 cisplatin-
induced renal damage,17 and rheumatoid arthritis18 are
manifested to a lesser extent in Mdk/ mice. Midkine
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reperfusion-induced renal damage19 and cisplatin-induced
renal damage in Mdk/ mice.17
We previously demonstrated thatMdk/mice exhib-
ited a striking reduction of neointima formation in a reste-
nosis model (carotid artery ligation), and this effect was
reversed by systemic midkine administration.20 In support
of these data, midkine antisense oligodeoxyribonucleotide
has been shown to suppress midkine induction and conse-
quently neointimal hyperplasia in a rabbit balloon denuda-
tion model.21 Midkine small interfering RNA (siRNA)
externally administered to a vein graft also dramatically
suppressed neointimal hyperplasia in rabbits.22 In all these
models, midkine expression is induced in the neointima,
particularly in proliferating smooth muscle cells, reaching a
maximum level at about 7 days after operation. Therefore,
midkine is essential for neointimal hyperplasia and a poten-
tial target for the treatment of restenosis, but little informa-
tion is available about the relativity between midkine and
neointimal hyperplasia caused by stenting in atheromatous
lesion. Here we addressed this question by using bare metal
stent implantation into hypercholesterolemic rabbits.
MATERIALS AND METHODS
Animal model and stent implantation. All animal
procedures were performed in accordance with protocols
approved by the Animal Ethics Committee of Nagoya
University. Male Japanese White rabbits (KBT Oriental,
Tokyo, Japan) weighing 3.5 to 4.0 kg were fed a 1.0%
cholesterol diet for 4 weeks before stent implantation. To
avoid in-stent thrombus formation, all animals received
aspirin (20 mg/d) from 2 days before the stent implanta-
tion procedure until euthanasia.
The animals were anesthetized by intramuscular ad-
ministration of ketamine (35 mg/kg) and xylazine (10
mg/kg). The right carotid arteries were surgically exposed,
and a 5F catheter was positioned in the abdominal aorta
through a 5F introducer sheath (Terumo, Tokyo, Japan).
The animals were systemically heparinized (200 IU/kg). A
0.014-inch guide wire (Japan Lifeline, Tokyo, Japan) was
subsequently introduced through this catheter and ad-
vanced to the external iliac artery, and then a 30-mm-long
Multi-Link (Guidant, Indianapolis, Ind) stent mounted
over the 3-mm balloon was implanted in the external iliac
artery and inflated for 20 seconds at 6 atm and 20 seconds
at 8 atm (stent/artery ratio 1.2:1.0).
Animals were killed with a lethal dose of anesthesia at 1,
3, 7, 14, and 28 days after stenting, and stented arterial sites
and contralateral unstented sites were excised for biochem-
ical, immunohistochemical, and morphometric analyses.
Antithrombotic regimen. All animals were pre-
treated with aspirin (20 mg orally) for 24 hours before the
stent implantation procedure until euthanasia. In addition,
heparin (200 IU/kg) was administered intra-arterially be-
fore the catheterization procedures.
Western blot analysis. The stented arteries were ex-
cised on the indicated day after operation snap-frozen in
liquid nitrogen after the stent struts were removed. Thetissues were ground into powder and then homogenized in
the lysis buffer (10mM Tris-HCl (pH 7.4) containing
150mM sodium chloride, 1% Triton X-100, and 1mM
phenylmethylsulfonyl fluoride). The supernatants of the
lysates obtained on centrifugation were applied to a 12%
sodium dodecylsulfate-polyacrylamide gel electrophoresis
(SDS-PAGE). The proteins were then transferred to nitro-
cellulose membranes. Midkine protein was detected with
goat antihuman recombinant midkine antibody (dilution,
1:1000), followed by horseradish peroxidase-labelled anti-
goat antibody (dilution, 1:5000). Blots were visualized
with an electrochemiluminescence (ECL) kit (Amersham,
Little Chalfont, UK). The density of each band was mea-
sured using the public domain Scion Image program.
RNA extraction and reverse transcription-polymerase
chain reaction. Total RNA of the stented artery and
contralateral iliac artery was isolated by using ISOGEN
(Nippon Gene, Toyama, Japan) according to the manufac-
turer’s instructions. RNA samples were dissolved in dieth-
ylpyrocarbonate-treated water, and the RNA concentration
in each sample was measured spectrophotometrically. Be-
fore the reverse transcription (RT), residual genomic DNA
was eliminated with DNase I (Takara Shuzo, Otsu, Japan).
Equal amounts of RNA underwent first-strand comple-
mentary DNA (cDNA) synthesis using Superscript III RT
(Invitrogen, Carlsbad, Calif). The cDNA product was used
for each polymerase chain reaction (PCR) reaction, which
was performed using a GeneAmp PCR System 9600 (Per-
kin Elmer, Norwalk, Conn) with the following program:
30 cycles of denaturing at 94°C for 30 seconds, annealing
at 57°C for 30 seconds, and elongation at 72°C for 60
seconds.
The PCR primer set for midkine was 5=-GTGGC-
CAAAAAGAAAGACAA-3= (forward) and 5=-CTAGTC-
CTTTGCCTTCCCTT-3= (reverse); the product size was
369 bp.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
was used as an internal control in the RT-PCR reaction
with the primers 5=-AGCCAAAAGGGTCATCATCT-3=
(forward) and 5=-CTTCTTGATGTCGTCATACT-3= (re-
verse). The product size was 436 bp.
The PCR products were electrophoresed on 1.5
mg/mL agarose gels containing 0.1 mg/mL ethidium
bromide, and the gels were photographed under ultraviolet
illumination. Semiquantitative analysis was done by densi-
tometric measurements, and the relative density was nor-
malized by the amount of GAPDH messenger RNA as an
internal control.
Histopathology and immunohistochemistry. Stented
arterial segments were excised and fixed for 24 hours with
10% paraformaldehyde. For morphologic analysis, they
were embedded en bloc inmethylmethacrylate and 50-m-
thick sections from the middle part of the stents were made
with a tungsten knife. The sections were stained with
hematoxylin and eosin or elastic von Gieson stain. For
immunohistochemistry, after stent struts were gently re-
moved with microforceps, the tissues were dehydrated,
embedded in paraffin, and then cut into 4-m-thick slices.
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against rabbit monocytes/macrophages (RAM-11; Dako,
Glostrup, Denmark), endothelial cells (CD31; Dako), or
smooth muscle cells (-smooth muscle actin; Dako). For
midkine immunostaining, we used chicken antihuman
midkine (immunoglobulin Y [IgY]), which recognizes rab-
bit midkine as a primary antibody and nonimmune chicken
IgY as a control.
For double immunofluorescent staining for midkine
and macrophage, the paraffin section was treated with
proteinase K for 5minutes, blocked with 10% goat serum in
phosphate-buffered saline (PBS) for 30 minutes, and then
incubated in the chicken antihuman midkine (IgY) over
night at 4°C, followed by Cy-3–labeled antichicken IgY
antibody for 30 minutes, mouse monoclonal antibody
(RAM-11) for 60 minutes, and then fluorescein isothiocya-
nate (FITC)–labeled antimouse IgG for 30 minutes.
Cell culture. Humanmonocyte THP-1 cells were cul-
tured in Roswell Park Memorial Institute (RPMI)-1640
medium (Sigma Chemical Co, St Louis, MO) supple-
mented with 10% fetal calf serum (FCS) in a humidified 5%
carbon dioxide atmosphere. To obtain differentiated
THP-1 macrophages, THP-1 cells were seeded in 35-mm
dishes (1.0  106 cells/dish) and incubated with phorbol
myristate acetate (PMA; WAKO, Osaka, Japan) at a con-
centration of 100nM or buffer (0.1% dimethyl sulfoxide,
solution of PMA) as a control for 24 hours.23 After incu-
bation, detached cells were removed by aspiration, and the
adherent cells were washed with ice-cold PBS, lysed in the
lysis buffer, kept on ice for 10 minutes, and centrifuged at
15000g for 10 minutes at 4°C. The supernatants then
underwent SDS-PAGE and Western blotting.
Elicitation of mouse peritoneal macrophages and
formation of oxidized low-density lipoprotein–induced
foam cells. Mouse peritoneal macrophages were elicited
by injecting 2 mL of 3% thioglycollate medium (WAKO)
intraperitoneally. Five days later, peritoneal lavages were
collected using 6 mL of ice-cold PBS. The cells were
centrifuged at 500g for 5 minutes at room temperature.
They were then suspended at 1.0  106 cells/mL in
RPMI-1640 medium containing 3% FCS, and 2-mL ali-
quots of the suspension were plated on 12-well dishes.
After a 90-minute incubation at 37°C in a humidified 5%
carbon dioxide, atmosphere, nonadherent cells were dis-
carded by washing with PBS. The cells were then incubated
in RPMI-1640 medium containing 3% FCS with or with-
out 100 g/mL LDL (Biomedical Technologies Inc,
Stoughton, Mass) or 100 g/mL oxLDL for 24 hours.
After that, the cells were lysed in radioimmunoprecipitation
assay (RIPA) buffer (50mM Tris-HCl, 150mM sodium
chloride, 1% Nonidet P, 1% deoxycholic acid, and 0.05%
SDS). The supernatants of the lysates underwent SDS-
PAGE and Western blotting.
Oil red O staining. Peritoneal-elicited macrophages
were seeded onto multiwell chamber slides (Nunc, Rosk-
ilde, Denmark) at a density of 6.0  105 cells/well in the
presence or absence of 100 g/mL LDL or oxLDL and
incubated for 24 hours. Then the cells were rinsed twicewith PBS, fixed with 10% formaldehyde, and stained with
0.5% oil red O (Sigma) in isopropanol for 20 minutes,
followed by counterstaining with hematoxylin. Lipid accu-
mulation was observed under a microscope.
Statistical analysis. All values are expressed as the
means  standard error of the means. Comparisons be-
tween two groups were performed with the unpaired Stu-
dent t test. Values of P  .05 were considered statistically
significant. Stat View 5.0 software (SAS Institute, Cary,
NC) was used for statistical calculations.
RESULTS
Hypercholesterolemic diet. The total plasma choles-
terol levels of the 14 rabbits that ate a high-cholesterol diet
for 4 weeks were significantly increased (1122  136
mg/dL) compared with those in the 10 control rabbits that
ate a normal diet (21.6  1.7 mg/dL, P  .0001).
Midkine expression was induced in an in-stent
restenosis model of hypercholesterolemic rabbits.
Rabbits were fed a 1% cholesterol diet for 28 days. A bare
metal stent was then implanted into the right external iliac
artery. Plain radiographs and angiography both showed
that the inserted artery was dilated 1.2-fold by the stent
(Fig 1, A). An artery obtained from a rabbit fed a normal
diet showed moderate neointimal hyperplasia, whereas that
from a rabbit fed a hypercholesterol diet exhibited marked
neointimal hyperplasia (Fig 1, B). A model in which ath-
erosclerosis is first induced and then treated by stenting
could be also used in this study, but we chose the present
model because it is one that is commonly used in which it is
easy to set up reproducible consistent conditions.
Midkine expression was evaluated by means of Western
blotting and RT-PCR. At both the protein and RNA levels,
midkine expression was enhanced 3 days after operation
and reached the maximum level at about 7 days (Fig 2).
Midkine was mainly expressed in infiltrating mac-
rophages. Chicken antihuman midkine antibody (IgY)
specifically recognizes rabbit midkine in Western blotting
(data not shown). On immunohistochemistry, the anti-
body stained a part of the neointima of hypercholester-
olemic rabbits, whereas control chicken IgY did not show
positive signals (Fig 3, A).
Specimens from rabbits at 7, 14, and 28 days after
operation were examined for expression of CD31 (endo-
thelium), -smooth muscle actin (smooth muscle),
RAM11 (macrophage), and midkine. Smooth muscle cells
were detected in a relatively upper layer (ie, near the endo-
thelium), whereas macrophages were localized in a deeper
layer (Fig 3, B). Midkine localization overlapped that of
macrophages (Fig 3, B). The double immunofluorescent
staining for midkine and macrophage confirmed that mac-
rophages express midkine (Fig 3, C).
We previously reported that midkine expression is de-
tected in normal endothelial cells as well as endothelial cells
after reendothelialization in the balloon-injury model.20
We also detected the expression in these cells as shown in
Fig 3, B(j-l). Magnified photos of Fig 3, B(c) and B(l) are
shown as an example in Fig 3, D.
rogen
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low-density lipoprotein. We freshly isolated human
monocytes from peripheral blood and examined midkine
Fig 1. Induction of neointimal hyperplasia by bare
radiographs and (b) angiography after stent implanta
B,Neointimal hyperplasia was induced moderately in a (
rabbit fed a hypercholesterol diet. Bar, 500 m.
Fig 2. Midkine expression during neointima formatio
obtained at the indicated number of days after stenting. T
as the average SE (n 4). *P .01; **P .0001 (Stud
chain reaction (RT-PCR) data were obtained from two i
control and day 7: n  4). Because the results of each se
A,Midkine protein expression revealed by Western blot
RT-PCR. GAPDH, Glyceraldehyde-3-phosphate dehydexpression in these cells. The expression was not detectable(data not shown). We then tested THP-1 cell differentia-
tion. THP-1, a human monocytic cell line, was exposed to
100nM PMA. The PMA-treated cells became flattened and
stent implantation. A, The arrows in the (a) plain
into the right iliac artery indicate the stented lesion.
bit fed a normal diet, but was markedly induced in a (b)
ght iliac arteries of hypercholesterolemic rabbits were
aphs show relative densitometric density ratios presented
test).Western blot and reverse transcription–polymerase
dual animals, respectively, at each time point (except for
xperiments were similar, representative data are shown.
sis. B,Midkine messenger RNA expression estimated by
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June 20081326 Narita et alFig 3. Protein localization in neointima hyperplasia. Immunohistochemistry data were obtained from three individual
animals at each time point. Because the results of each set of experiments were similar, representative data are shown.
A, Chicken antihuman midkine antibody (upper) or control chicken immunoglobulin (Ig) Y was used as the first
antibody to localize midkine protein expression in an artery obtained 14 days after operation. Note that IgY did not
show any signals. Bar, 100 m. B, The indicated antibodies were used to localize their target proteins in the specimen.
The midkine protein localization overlapped that of macrophages (RAM11). Bars, 100 m. -SMA, -Smooth muscle
actin. C, The double immunofluorescent staining for midkine and macrophage was performed on specimens 7 days
after stenting. S indicates stent strut. Bar, 20 m. D, Midkine protein was localized to the endothelium. Magnified
photos of B, c and B, l are shown. Bar, 20 m.
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However, PMA treatment did not enhancemidkine expres-
sion, but THP-1 cells expressed a significant amount of
midkine (Fig 4, B).
Because oxLDL is recognized by a scavenger receptor
on macrophages and initiates atherosclerosis, we finally
examined the effect of oxLDL on midkine expression in
macrophages. The elicited peritoneal macrophages were
collected after activation with thioglycollate and then ex-
posed to oxLDL or LDL at 100 g/mL for 24 hours.
Macrophages exposed to oxLDL showed marked lipid
droplet staining, indicating that the combination of oxLDL
and peritoneal macrophages mimics an early stage of ath-
erosclerosis (Fig 5, A). Even if macrophages expressed a
significant amount of midkine, oxLDL treatment did not
significantly enhance midkine expression (Fig 5, B).
As we have shown, THP-1 cells and elicited peritoneal
macrophages, but not freshly isolated human monocytes,
expressed a significant amount of midkine. Because both
THP-1 cells and peritoneal macrophages have established
some level of differentiation, our data may suggest that
midkine expression is induced during differentiation to
macrophages.
DISCUSSION
Recent studies have emphasized the involvement of
inflammation and the proliferation of vascular smoothmus-
cle cells in atherosclerosis and restenosis.24,25 We previ-
Fig 4. Midkine expression during differentiation of mon
were treated with either (left) dimethyl sulfoxide (DMS
B,Western blot analysis for midkine protein expression. T
densitometric density ratio (n  4).ously reported marked suppression of neointima hyperpla-sia in Mdk/ mice and also striking suppression of
neointima hyperplasia in rabbit models by midkine expres-
sion knockdown.20-22 In addition, induction of midkine
expression is associated with expression of chemokines,
such as macrophage inflammatory protein-2 and monocyte
chemotactic protein-1, in an ischemic renal injury model.16
The expression of thesemolecules is suppressed inmidkine-
deficient mice, and consequently, tubulointerstitial damage
is strikingly suppressed.16 Consistent with this finding,
recruitment of neutrophils and monocytes/macrophages
to the arterial wall and the kidney is reduced in an arterial
restenosis model and an ischemic renal injury model, re-
spectively, in midkine-deficient mice.6,20 Furthermore,
midkine exhibits a chemotactic activity toward neutrophils,
macrophages, and vascular smooth muscle cells.20,26 The
present study has shown that midkine expression is closely
associated with macrophage accumulation in neointimal
hyperplasia of hypercholesterolemic rabbits. Together with
these previous reports, our present findings indicate that
midkine plays an important role in neointimal hyperplasia.
We found in this study that themajor source of midkine
in the neointima of atherosclerotic vessels was infiltrating
macrophages rather than proliferating smooth muscle cells.
This finding conflicted with previous reports in which
midkine was mainly expressed in proliferating smooth mus-
cle cells in restenosis models with a normal diet,20-22
whereas our finding of a correlation between activated
macrophages and midkine was in agreement with earlier
c cells.A, Phase-contrast photos are shown. THP-1 cells
(right) phorbol myristate acetate (PMA) for 24 hours.
aph at right shows the average SE values of the relativeocyti
O) or
he grstudies on the elicited peritoneal macrophages.27,28 We
no sig
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stages initiates a chain reaction that involves several mole-
cules and induces inflammation in the vessel wall, and that
this chain reaction consequently plays a critical role in
neointima formation.21,22 This mechanismmay still be vital
in restenosis in hypercholesterolemic animals, but the
present results strongly suggest that midkine expressed in
infiltrating macrophages directly induces smooth muscle
cell migration from the media to the intima. Although
midkine does not enhance proliferation of vascular smooth
muscle cells, it enhances both the migration of macro-
phages and, with the help of unknown factor(s) secreted
from vascular smooth muscle cells, the migration of vascu-
lar smooth muscle cells as well.20
Many molecular target-oriented therapies for vascular
restenosis have been proposed so far. For example, E2F
decoy oligodeoxyribonucleotide is expected to suppress the
proliferation of vascular smooth muscle cells and has shown
encouraging results in a clinical trial for human bypass vein
grafts.29,30 In animal in-stent restenosis models, manymol-
ecules associated with vascular inflammation have been
suggested to be good candidate targets for prevention of
in-stent restenosis, including platelet-derived growth fac-
tor,31 interleukin-10,32 	2-integrin Mac-1,33 transform-
ing growth factor-	,34 and monocyte chemoattractant
protein-1.34 Because midkine is barely expressed in human
adult organs, it could be a good target that could avoid
serious adverse effects.
We previously locally administered siRNA onto the
vessel wall in a vein graft model by wrapping the vessel with
siRNA-containing atelocollagen and obtained striking sup-
pression of intimal hyperplasia.22 But in the present setting,
a stent releasing siRNA would be an ideal method to
prevent stenosis. Although many obstacles still remain,
many laboratories including ours are currently trying to
Fig 5. Effect of oxided low-density lipoprotein cho
A, Peritoneal macrophages were exposed to 100 g/mL
oil red O to detect lipid droplets in the cell. Note th
B, Midkine expression was estimated by Western blot an
relative densitometric density ratio (n  4). There weredevelop a stent that releases siRNA.The mechanisms underlying midkine-mediated migra-
tion of smooth muscle cells remain to be verified. Protein
tyrosine phosphatase-
, a receptor-type protein tyrosine
phosphatase with chondroitin sulfate chains, is involved in
midkine-mediated cell migration.35-37 Midkine also syner-
gistically functions with platelet-derived growth factor
(PDGF) in cell migration.37 PDGF is implicated in neoin-
tima formation and atherosclerosis,38-40 and PDGF recep-
tor 	 is negatively regulated by LDL receptor-related pro-
tein,41 which is a receptor for midkine.42,43 Thus, mice
deficient in LDL receptor-related protein exhibit enhanced
atherosclerosis,41 Further elucidation of the mechanism of
midkine-mediated migration of smooth muscle would
speed the development of new therapeutics for vascular
restenosis.
CONCLUSION
Midkine may have an important role for intimal hyper-
plasia caused by bare metal stent implantation through a
macrophage accumulation and be a novel molecular target
to prevent in-stent restenosis.
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